Autolus Therapeutics Plc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Autolus Therapeutics Plc's ROI in the second quarter of 2026?
Autolus Therapeutics Plc recorded a cumulative net loss of $-280 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -56.48%.

Within the Healthcare sector 281 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3219 to 3666.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	-29.88 %	-25.99 %	-23.31 %	3 %	31.59 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	424	463	517	579	653
Return On Investment (TTM)	-56.48 %	-52.24 %	-47.35 %	-34.15 %	-32.2 %
AUTL's Overall Ranking	# 3666	# 3219	# 3247	# 3358	# 3052
Seq. Investment Change TTM	-10.32 %	-8.9 %	-7.77 %	-6.93 %	-5.35 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-280	-289	-288	-225	-228

AUTL Company Profile >> Back to AUTL Roi Comparisons >> See Annual AUTL Return On Investment

Return On Investment AUTL's Ranking
Within:	No.
Industry	# 38
Sector	# 282
Overall	# 3666

Return On Investment Statistics
High	Average	Low
-26.29 %	-45.59 %	-82.63 %
(Dec 31 2024)		(Sep 30 2023)

Financial Statements
Autolus Therapeutics Plc's II. Quarter Investments	$ 424 Millions	AUTL's Balance sheet
Autolus Therapeutics Plc's II. Quarter Income	$ -39 Millions	Quarterly AUTL's Income Statement
AUTL's Income by Division		See AUTL's Income by Division

AUTL Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	517	722	111	444	377
Y / Y Investment Growth	-28.33 %	547.67 %	-74.89 %	17.74 %	79.5 %
Net Income in Millions	-288	-221	-208	-149	-142
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-55.57 %	-30.56 %	-186.93 %	-33.53 %	-37.69 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Biotechnology & Pharmaceuticals Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
AUTL's Roi Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for AUTL's Competitors
Subscribers only: Roi for Autolus Therapeutics Plc's Suppliers
Subscribers only: Return On Investment for AUTL's Customers

Other Ratios
AUTL's Roa	AUTL's Inventory Turnover Ratio	AUTL's Growth Rates	AUTL's Dividend Statistics
	AUTL's Profitability Ratios	AUTL's Asset Turnover Ratio	AUTL's Dividend Growth
AUTL's Roe	AUTL's Valuation Ratios	AUTL's Financial Strength Ratios	AUTL's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector

ROI

Date modified: 2026-09-26T07:39:01+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.